← All trials
NCT05852873
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 12, 2023
- Primary completion
- Apr 30, 2024
- Completion date
- Apr 30, 2026
- First posted
- May 10, 2023
- Last posted
- Oct 18, 2023
- Enrollment
- 2000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of BergenLead sponsor
- Norwegian University of Science and TechnologyCollaborator
- Norwegian University of Science and TechnologyCollaborator
- University of OsloCollaborator
- University of OsloCollaborator
- University of BergenCollaborator
- University of BergenOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.